OR WAIT null SECS
Manufacturing capacity will be increased by one third and approximately 300 new high-wage and highly-skilled jobs will be created at the Fremont site.
Boehringer Ingelheim announced on July 21, 2017 that it has allocated $217 million for the upgrade and expansion its biologics manufacturing facility in Fremont, California. Manufacturing capacity will be increased by one third, according to the company. It will also create approximately 300 new high-wage and highly-skilled jobs at the Fremont site, which was recently awarded $25.5 million in two separate tax credits from the State of California.
“The Bay Area is the largest biotech cluster in the world. We are happy to have made Fremont our home and are grateful for the support we have received from the community and the State of California,” said Jens Vogel, President and CEO of Boehringer Ingelheim Fremont, in a press release. “We have made a commitment to the region and are excited to continue to invest in the Bay Area and expand our workforce to help increase patient access to high-quality medicines.”
“The State Treasurer’s Office is excited to play a role in helping Boehringer Ingelheim expand and create nearly 300 permanent, high-paying jobs right here in California,” State Treasurer John Chiang commented in the same press release. “The incentives my office provides ensure that California will retain and create jobs, bolster the economy, and clean the environment, today and into the future.”
Boehringer Ingelheim invests nearly 20% of all net sales back into research and development. The Fremont facility focuses on the manufacture of medicines for immunology, rheumatology, and oncology. It covers biopharmaceutical development and manufacturing from small scale to commercial, from drug substance manufacturing to fill/finish, packaging, and medical device assembly.
Source: Boehringer Ingelheim